New antibody injection targets Hard-to-Treat cancers in early trial
NCT ID NCT06609187
First seen Jan 22, 2026 · Last updated May 25, 2026 · Updated 19 times
Summary
This early-phase study tests a new drug called GNC-077 in 20 people with advanced breast cancer or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants must have a tumor that can be measured and provide a tissue sample for testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.